FR2757400B1 - APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS - Google Patents

APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS

Info

Publication number
FR2757400B1
FR2757400B1 FR9615649A FR9615649A FR2757400B1 FR 2757400 B1 FR2757400 B1 FR 2757400B1 FR 9615649 A FR9615649 A FR 9615649A FR 9615649 A FR9615649 A FR 9615649A FR 2757400 B1 FR2757400 B1 FR 2757400B1
Authority
FR
France
Prior art keywords
antiglucocorticoidal
psychosis
compounds
treatment
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9615649A
Other languages
French (fr)
Other versions
FR2757400A1 (en
Inventor
Claude Oberlander
Pier Vincenzo Piazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9615649A priority Critical patent/FR2757400B1/en
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Priority to AU55633/98A priority patent/AU5563398A/en
Priority to PCT/FR1997/002321 priority patent/WO1998026785A1/en
Priority to EP97952079A priority patent/EP0918525A1/en
Priority to EP97952078A priority patent/EP0892641A1/en
Priority to AU55632/98A priority patent/AU5563298A/en
Priority to PCT/FR1997/002320 priority patent/WO1998026783A1/en
Publication of FR2757400A1 publication Critical patent/FR2757400A1/en
Application granted granted Critical
Publication of FR2757400B1 publication Critical patent/FR2757400B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FR9615649A 1996-12-19 1996-12-19 APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS Expired - Fee Related FR2757400B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9615649A FR2757400B1 (en) 1996-12-19 1996-12-19 APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS
PCT/FR1997/002321 WO1998026785A1 (en) 1996-12-19 1997-12-17 Use of mifepristone for the treatment of psychoses and addictive behaviours
EP97952079A EP0918525A1 (en) 1996-12-19 1997-12-17 Use of mifepristone for the treatment of psychoses and addictive behaviours
EP97952078A EP0892641A1 (en) 1996-12-19 1997-12-17 Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours
AU55633/98A AU5563398A (en) 1996-12-19 1997-12-17 Use of mifepristone for the treatment of psychoses and addictive behaviours
AU55632/98A AU5563298A (en) 1996-12-19 1997-12-17 Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours
PCT/FR1997/002320 WO1998026783A1 (en) 1996-12-19 1997-12-17 Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615649A FR2757400B1 (en) 1996-12-19 1996-12-19 APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS

Publications (2)

Publication Number Publication Date
FR2757400A1 FR2757400A1 (en) 1998-06-26
FR2757400B1 true FR2757400B1 (en) 1999-12-17

Family

ID=9498861

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9615649A Expired - Fee Related FR2757400B1 (en) 1996-12-19 1996-12-19 APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS

Country Status (4)

Country Link
EP (2) EP0892641A1 (en)
AU (2) AU5563398A (en)
FR (1) FR2757400B1 (en)
WO (2) WO1998026785A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747956B2 (en) 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
SK287535B6 (en) 1999-04-30 2011-01-04 Pfizer Products Inc. Glucocorticoid receptor modulators
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
MXPA04000692A (en) * 2001-07-23 2004-04-21 Corcept Therapeutics Inc Methods for preventing antipsychotic-induced weight gain.
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
EP1862468A1 (en) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Crystalline 11beta-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-one
DE102009034367A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases
DE102009034362A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034366A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034525A1 (en) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034526A1 (en) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102010007719A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
DE102010007722A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
EP2576582B1 (en) * 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
CN118251415A (en) * 2021-10-29 2024-06-25 清华大学 Methods and products for treating or diagnosing schizophrenia
CN114652730A (en) * 2021-12-08 2022-06-24 中国科学院深圳先进技术研究院 Use of mifepristone for intervention and treatment of nicotine addiction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687088B2 (en) * 1993-08-04 1998-02-19 Merck Sharp & Dohme B.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
FR2718354B1 (en) * 1994-04-08 1996-05-03 Roussel Uclaf Application of the anti-glucocorticoid compounds for the preparation of medicaments intended for the prevention or the treatment of the manifestations linked to the narcotic withdrawal syndrome and the compositions containing them.

Also Published As

Publication number Publication date
EP0892641A1 (en) 1999-01-27
WO1998026785A1 (en) 1998-06-25
AU5563298A (en) 1998-07-15
WO1998026783A1 (en) 1998-06-25
FR2757400A1 (en) 1998-06-26
AU5563398A (en) 1998-07-15
EP0918525A1 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
FR2757400B1 (en) APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS
NO991381D0 (en) Combination therapy for the treatment of psychoses
DK0736075T3 (en) The antifouling agent
DE69421296D1 (en) MELT TREATMENT
NO972909D0 (en) Substituted azetidin-2-ones for the treatment of atherosclerosis
BR9505368A (en) Cosmetic or dermatogogic composition water-in-oil
HUP0003851A3 (en) Pharmaceutical composition for the treatment or prevention of glomerulopathy
DE69413051D1 (en) DETERGENT COMPOSITIONS CONTAINING AGENTS FOR PREVENTING THE TURNING OF SILVER
BR9609445A (en) Azetidinone derivatives in the treatment of atherosclerosis
FI963596A (en) Reduction of excess chloride from the oxide in iron
ITMI931436A1 (en) HOMOCINETIC REVOLVING JOINT
BR9604818A (en) Combination compositions containing benazepril or benazeprilat and valsartan
ID16981A (en) THE CONCENTRATES OF ENCER PEARLS
FI970205A0 (en) The two-hybrid system
FI964809A0 (en) In the case of use of the processing unit
ID17201A (en) PROCESSES AND TOOLS FOR SKIN TREATMENT AND THE LIKE
KR950011076U (en) Bearing detacher
BR9103853A (en) COATING OR COATING STONE
FR2701976B1 (en) Work protected from bad weather, in particular work for the burial of waste.
KR970054943U (en) The Ossuary Complex of the Ossuary Hall
FI960317A0 (en) Procedure for the treatment of hazardous waste
KR940025597U (en) Outlet safeguard
KR960007445U (en) The outer handle of the car door
KR950006369U (en) Industrial Water Treatment
KR960021252U (en) Torque limiter built-in reducer

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse

Effective date: 20111209